The clinical development pipeline for Alzheimer’s disease (AD) represents one of the highest-stakes, most capital-intensive, and historically volatile sectors in the biopharmaceutical industry. As the global population ages, the clinical and economic urgency to develop effective disease-modifying therapies (DMTs) has intensified. Navigating this pipeline requires a rigorous, data-driven understanding of the clinical trial registry: how many trials are active, what molecular mechanisms are being targeted, who is sponsoring the research, and what key clinical catalysts are on the horizon.
To provide business development (BD) scouts, pipeline analysts, clinical operations leaders, and biotech investors with a reproducible map of the Alzheimer's clinical trial landscape, we conducted a systematic analysis of the ClinicalTrials.gov registry. By auditing the registry's global dataset, we isolated the historical and active clinical trial footprint for Alzheimer’s disease.
This briefing reconciles the raw registry data against the authoritative annual pipeline review (the Cummings 2026 snapshot) and integrates critical clinical updates—including the landmark FDA approvals of Leqembi and Kisunla, the April 2026 Cochrane systematic review, and the pivotal readouts scheduled for late 2026. It extends our clinical-trials-by-the-numbers franchise, applying the same registry method we have used for cell and gene therapy clinical trials by the numbers and anti-obesity Phase 3 pipeline clinical trials.
BD & Licensing Executive Summary
- How large is the Alzheimer's trial registry? ClinicalTrials.gov contains 3,542 registered trials targeting Alzheimer’s disease or mild cognitive impairment (MCI).
- Which phases dominate the registry? Of the phased trials in the registry, Phase 2 is the largest single-phase category with 532 trials, followed by Phase 1 (439 trials) and Phase 3 (288 trials). Additionally, 508 trials are specifically tagged as evaluating mild cognitive impairment (MCI).
- Who are the leading sponsors? A total of 1,228 trials are industry-sponsored, with Pfizer (54 trials), Eli Lilly and Company (52 trials), and Avid Radiopharmaceuticals (42 trials) leading the commercial footprint.
- How does this compare to the active pipeline? The authoritative Cummings 2026 pipeline snapshot counts 192 active clinical trials evaluating 158 novel agents (up from 182 trials of 138 agents in 2025). Of these, disease-modifying therapies (DMTs) account for 73% of the agents.
- What are the key 2026 catalysts? The 2026 readout calendar features 8 Phase 3 trials and 29 Phase 2 trials completing this year. Key catalysts include the AHEAD 3-45 prevention trial (lecanemab), the DIAN-TU E2814 anti-tau trial, the ALTITUDE-AD sabirnetug trial, the TRAILRUNNER-ALZ1 remternetug trial, and the registrational ALZ-801/APOLLOE4 trial.
- What is the latest clinical consensus? An April 16, 2026 Cochrane systematic review of 17 anti-amyloid monoclonal antibody (mAb) trials involving over 20,000 participants concluded that the absolute cognitive benefits of these agents are "absent or trivial" relative to the clinical risks, primarily Amyloid-Related Imaging Abnormalities (ARIA).
How many Alzheimer's clinical trials are in ClinicalTrials.gov, and how do the phases break down?
Our systematic filter of the ClinicalTrials.gov registry identified exactly 3,542 trials that target Alzheimer's disease or related mild cognitive impairment. This registry cut represents the all-time historical accumulation of clinical trials registered in the database. To establish a clean cohort, our query targeted trials containing "alzheimer" (case-insensitive) in the primary conditions field. Of this cohort, 508 trials specifically tag "mild cognitive impairment" (MCI) or "prodromal Alzheimer's disease," reflecting the industry's shift toward testing therapies in earlier, pre-dementia stages of the disease.
To understand the developmental lifecycle of Alzheimer's therapeutics, we segmented the 3,542 registry trials by their clinical phase. The table below details the phase distribution:
| Clinical Phase | Trial Count | Share of Registry (%) | Primary Clinical Objectives |
|---|---|---|---|
| Phase 1 | 439 | 12.4% | First-in-human safety, tolerability, pharmacokinetics, and dose-escalation. |
| Phase 1/Phase 2 (Combined) | 94 | 2.7% | Early safety expansion and exploratory efficacy signaling. |
| Phase 2 | 532 | 15.0% | Efficacy cohort evaluation, biomarker changes, dose optimization, and safety monitoring. |
| Phase 2/Phase 3 (Combined) | 58 | 1.6% | Seamless adaptive designs transitioning from cohort finding to registrational. |
| Phase 3 | 288 | 8.1% | Large-scale registrational trials, head-to-head vs. placebo or standard care. |
| Phase 4 | 126 | 3.6% | Postmarket surveillance, safety registries, and real-world outcomes. |
| Early Phase 1 (Phase 0) | 59 | 1.7% | Exploratory microdosing, tracer validation, and biodistribution tracking. |
| NA / Not Phased | 1,192 | 33.7% | Behavioral interventions, dietary supplements, diagnostic tracers, and observational registries. |
| Blank / Unspecified | 754 | 21.3% | Older registry records or legacy trials without formal phase metadata. |
| Total Alzheimer's Registry | 3,542 | 100.0% | Comprehensive historical and active AD trial footprint. |
The phase distribution reveals a pronounced translational bottleneck. While Phase 1 and Phase 2 trials account for a combined 971 trials (excluding combined/seamless phases), the registrational pipeline narrows significantly to 288 Phase 3 trials. This steep drop-off illustrates the high attrition rate that has historically plagued neurodegenerative drug development.
The large volume of "NA" and "Blank" entries (1,946 trials) is a crucial structural characteristic of the registry. This category is not composed of investigational drugs; rather, it reflects the diverse, non-pharmacological efforts to address Alzheimer's, including cognitive behavioral therapy, caregiver support interventions, digital health monitoring, and diagnostic imaging validation (such as PET tracer development).
Which mechanisms of action dominate the Alzheimer's pipeline?
To analyze the therapeutic strategies deployed in Alzheimer's clinical trials, we executed a mechanism-focused keyword scan across the intervention descriptions and trial titles of the 3,542 registry records. This analysis highlights how clinical focus has shifted over time from basic symptomatic relief to targeted disease-modifying agents and next-generation modalities.
The table below breaks down the registry cohort by major mechanism and intervention category:
| Mechanism / Intervention Category | Trial Count | Share of Registry (%) | Key Molecular Targets / Examples |
|---|---|---|---|
| Symptomatic Neurotransmitter / Synaptic | 252 | 7.1% | Cholinesterase inhibitors (donepezil, galantamine), NMDA antagonists (memantine), 5-HT receptor antagonists (lecozotan). |
| Lifestyle / Cognitive / Behavioral | 215 | 6.1% | Cognitive training, diet, exercise, cardiovascular management, sleep interventions. |
| Anti-Tau / Tau Aggregation | 96 | 2.7% | Monoclonal antibodies targeting tau (E2814, bepranemab), aggregation inhibitors, microtubule stabilizers. |
| Anti-Amyloid Monoclonal Antibodies (mAbs) | 94 | 2.7% | Beta-amyloid targeting mAbs (lecanemab, donanemab, remternetug, aducanumab, crenezumab, gantenerumab, solanezumab, bapineuzumab). |
| GLP-1 / Incretin Repurposing | 10 | 0.3% | Glucagon-like peptide-1 receptor agonists (semaglutide, liraglutide) evaluating neuroprotective and anti-inflammatory properties. |
| BACE / Gamma-Secretase Inhibitors | 9 | 0.3% | Beta-site amyloid precursor protein cleaving enzyme inhibitors (verubecestat, lanabecestat) and secretase modulators. |
| Anti-Inflammatory / Anti-TLR / NSAIDs | 8 | 0.2% | Microglial modulators, Toll-like receptor (TLR) antagonists, non-steroidal anti-inflammatory drugs. |
| Gene Therapy / Adeno-Associated Virus (AAV) | 7 | 0.2% | Gene-delivery vectors targeting neurotrophic factors (NGF, BDNF) or modifying APOE alleles (APOE2 gene transfer). |
The Amyloid-Tau Axis
For the past two decades, disease-modifying research has been dominated by the amyloid cascade hypothesis. Anti-amyloid mAbs (94 trials) have advanced furthest, resulting in the approvals of Leqembi (lecanemab) and Kisunla (donanemab). However, the high failure rate of amyloid-clearing agents has led to the expansion of anti-tau programs (96 trials), which focus on preventing the intracellular propagation of hyperphosphorylated tau tangles—a pathology that correlates much more closely with cognitive decline than amyloid plaque burden.
Metabolic Repurposing
A newer, high-interest segment is the repurposing of incretin mimetics, such as GLP-1 receptor agonists (10 trials). Epidemiological data and preclinical models suggesting that Alzheimer's is characterized by cerebral insulin resistance (often termed "Type 3 diabetes") have driven trials of semaglutide to evaluate its impact on neuroinflammation and cognitive decline.
Which sponsors are running the most Alzheimer's trials?
The commercial landscape of Alzheimer's clinical trials is split between a concentrated group of large biopharmaceutical companies and specialized imaging developers on one side, and academic and hospital networks on the other. Of the 3,542 trials in the registry, 1,228 trials are classified as industry-sponsored, representing 34.7% of the total volume. Academic institutions, hospital networks, and non-profit organizations sponsor the majority (2,138 trials), reflecting the extensive role of investigator-initiated trials in validating early-stage mechanisms, biomarkers, and non-pharmacological interventions. The National Institutes of Health (NIH) directly sponsors 64 trials, and other federal agencies sponsor 37 trials.
The list below details the top industry sponsors in the Alzheimer's trial registry:
- Pfizer: 54 trials (complemented by 27 trials registered under its wholly owned subsidiary, Wyeth, totaling 81 trials). Pfizer was a pioneer in early symptomatic trials (donepezil/Aricept) and bapineuzumab.
- Eli Lilly and Company: 52 trials. Lilly's portfolio spans donanemab (Kisunla), remternetug, and the landmark Avid imaging trials.
- Avid Radiopharmaceuticals: 42 trials. Acquired by Eli Lilly in 2010, Avid pioneered the development of florbetapir (Amyvid), the PET imaging agent that revolutionized clinical trials by allowing visual verification of amyloid pathology in living patients.
- Merck Sharp & Dohme LLC: 31 trials. Merck’s pipeline historically focused on BACE inhibitors (verubecestat) and symptomatic compounds.
- GlaxoSmithKline (GSK): 29 trials. Focused on vaccine formulations, immunotherapeutics, and symptomatic compounds.
- Hoffmann-La Roche: 26 trials. Roche’s portfolio includes gantenerumab and crenezumab, alongside active bispecific antibody shuttle programs.
- AstraZeneca: 24 trials. Collaborations in BACE inhibitors and novel small-molecule candidates.
- Eisai Inc.: 22 trials. Eisai partnered with Pfizer on Aricept and is the primary developer of Leqembi (lecanemab) in partnership with Biogen.
- Novartis Pharmaceuticals: 21 trials (complemented by an additional 14 trials registered under "Novartis", totaling 35 trials).
- Bristol-Myers Squibb (BMS): 20 trials. Historically active in gamma-secretase inhibitors and early disease-modifying assets.
While academic institutions manage a larger share of early-stage trials, industry sponsors dominate late-stage development. The Cummings 2026 pipeline review reports that the biopharmaceutical industry sponsors 59% of all active Alzheimer's trials and roughly 72% of active Phase 3 trials. This shift highlights the high cost of running global, multi-year Phase 3 trials, which require advanced PET imaging, CSF biomarker testing, and large patient cohorts.
How does the registry count compare with the Cummings 2026 pipeline snapshot?
A common analytical error among pipeline watchers is conflating the historical registry counts in ClinicalTrials.gov with the active drug development pipeline. The registry count of 3,542 trials is an all-time historical denominator that includes completed, terminated, and observational trials spanning more than 25 years.
To provide a precise, real-time snapshot of active commercial drug development, analysts rely on the authoritative annual pipeline review published by Dr. Jeffrey Cummings and colleagues (the Cummings 2026 pipeline snapshot). Reconciling these two datasets is essential for accurate pipeline sizing and competitive intelligence.
| Metric | ClinicalTrials.gov Registry Cut (All-Time) | Cummings 2026 Pipeline Snapshot (Active) |
|---|---|---|
| Scope / Focus | All registered historical, completed, active, and terminated trials of all interventions (drugs, devices, behavioral, dietary). | Active clinical trials of novel, investigational pharmacological agents targeting Alzheimer’s disease as of January 1, 2026. |
| Total Volume | 3,542 trials | 192 active clinical trials evaluating 158 novel agents (representing a notable increase from the 182 trials and 138 agents tracked in 2025). |
| Phase Mix | Phase 1: 439 | Phase 2: 532 | Phase 3: 288 | Other/NA: 2,283. | Phase 1: 49 trials (45 agents) | Phase 2: 89 trials (84 agents) | Phase 3: 54 trials (36 agents). |
| Therapeutic Split | Non-pharmacological and imaging tracers represent ~50% of the registry. | Disease-modifying therapies (DMTs): 73% (115 agents) | Cognition-enhancing symptomatic: 18% (28 agents) | Neuropsychiatric symptomatic: 10% (15 agents). |
| Modality Split | Mixed (devices, behavioral, natural products). | Small-molecule disease-targeting therapies: 39% of agents | Biologic disease-targeting therapies (mAbs, gene therapies): 34% | Symptomatic therapies (cognition + neuropsychiatric): 27%. |
| Clinical Trial Status | Completed: 1,870 | Recruiting: 514 | Terminated: 289 | Unknown/Other: 869. | All trials are active (recruiting, active-not-recruiting, or planned near-term). |
Reconciling the Denominators
The Cummings 2026 pipeline snapshot isolates the commercially relevant pharmacological pipeline by applying strict filters: it excludes standard diagnostic tracers, generic drugs undergoing bioequivalence testing, non-pharmacological behavioral therapies, and discontinued programs.
The Cummings review shows that the pipeline is growing: the number of active agents rose from 138 in 2025 to 158 in 2026, with 20 net new agents entering the active pipeline. Phase 2 is the largest active bucket (89 trials of 84 agents), indicating that drug developers are feeding new mechanisms (anti-tau, anti-inflammatory, synaptic plasticity) into mid-stage trials to diversify away from beta-amyloid monotherapy.
Which Phase 3 and Phase 2 readouts land in 2026, and why do they matter?
The year 2026 represents a critical regulatory and clinical crossroads for Alzheimer's R&D, with 8 Phase 3 trials and 29 Phase 2 trials scheduled for completion. The outcomes of these studies will determine whether the industry can advance beyond the first-generation anti-amyloid mAbs or if next-wave mechanisms will face the same translational hurdles as their predecessors.
The table below details the pivotal trials with major data readouts in 2026:
| Trial Name / NCT ID | Sponsor | Agent | Mechanism of Action | Phase | Estimated Completion | Clinical Relevance & Trial Design Details |
|---|---|---|---|---|---|---|
| AHEAD 3-45 NCT04468659 |
Eisai / Biogen | Lecanemab | Anti-amyloid mAb (protofibril selective) | Phase 3 | Late 2026 | Primary Prevention: Evaluating whether initiating treatment in cognitively unimpaired individuals with intermediate or elevated amyloid levels can delay cognitive decline. This shifts anti-amyloid intervention from treatment to prevention. |
| TRAILRUNNER-ALZ1 NCT05462860 |
Eli Lilly | Remternetug | Anti-amyloid mAb (N3pG-amyloid selective) | Phase 3 | Mid 2026 | Next-Gen Amyloid Clearance: Evaluating a next-generation mAb administered via subcutaneous injection (SQ) or intravenous infusion (IV). SQ administration could significantly reduce infusion clinic burdens and improve payer coverage options. |
| APOLLOE4 NCT04770220 |
Alzheon | ALZ-801 (Valiltramiprosate) | Amyloid oligomer inhibitor (oral) | Phase 3 | Late 2026 | Oral Disease Modification: A registrational trial evaluating an oral small molecule in patients homozygous for the APOE4 allele (highest risk group). Offers a potential oral alternative to IV mAbs, without the associated risk of ARIA-E. |
| DIAN-TU E2814 NCT05269394 |
WashU / Eisai | E2814 | Anti-tau mAb (microtubule-binding domain) | Phase 2 | Late 2026 | Combination Therapy: Evaluating E2814 alone and in combination with lecanemab in dominant inherited Alzheimer's disease (DIAD). Serves as a major test of the amyloid-tau combination thesis. |
| ALTITUDE-AD NCT06008184 |
AC Immune | Sabirnetug (ACI-24.060) | Anti-amyloid active vaccine | Phase 2 | Late 2026 | Active Immunotherapy: Evaluating an active vaccine designed to stimulate the patient's own immune system to produce oligomer-selective antibodies. Successful active vaccines could lower treatment costs and reduce dosing frequency. |
Subcutaneous Delivery (TRAILRUNNER-ALZ1)
The clinical translation of anti-amyloid therapies has been hindered by the operational bottlenecks of monthly or bi-weekly intravenous infusions. Subcutaneous formulations of remternetug and lecanemab represent a major commercial focus. Successful subcutaneous readouts could expand the outpatient market and alter payer coverage strategies by shifting administration from the medical benefit to the pharmacy benefit.
The Combination Frontier (DIAN-TU E2814)
Because Alzheimer's is a multi-factorial disease, single-agent therapy is unlikely to reverse advanced dementia. The DIAN-TU E2814 trial is a pioneer in combination clinical trial design, testing whether clearing amyloid plaques while simultaneously blocking tau propagation yields synergistic cognitive benefits.
What does the April 2026 Cochrane review mean for the anti-amyloid thesis?
While the FDA approvals of Eisai's Leqembi (lecanemab) on July 6, 2023, and Eli Lilly's Kisunla (donanemab) on July 2, 2024, established the first disease-modifying treatments for early symptomatic Alzheimer's, the clinical and commercial debate surrounding their absolute benefit remains intense.
This tension was highlighted on April 16, 2026, when the Cochrane Database of Systematic Reviews published a major meta-analysis evaluating the clinical efficacy and safety of anti-amyloid monoclonal antibodies.
Key Findings of the Cochrane Review
- Efficacy Assessment: The systematic review analyzed 17 trials involving 20,342 participants. It concluded that while anti-amyloid mAbs successfully clear brain amyloid plaques, the associated reductions in cognitive decline are "absent or trivial." On standardized cognitive scales, the pooled effect was tiny — for example, a standardized mean difference of about 0.11 on the ADAS-Cog, which Cochrane classified as a "trivial or null" effect that falls well below the minimum clinically important difference.
- Safety Concerns: The review highlighted a significant increase in Amyloid-Related Imaging Abnormalities (ARIA). In the donanemab and lecanemab trials, approximately 20% to 35% of treated patients developed ARIA-E (edema) or ARIA-H (microhemorrhages). While most ARIA cases were asymptomatic and detected only via mandatory routine MRI scans, a subset of patients experienced severe neurological symptoms, and several patient deaths were linked to ARIA in the open-label extension phases.
- Risk-Benefit Balance: Cochrane's independent analysis concluded that the modest potential delay in cognitive decline does not outweigh the risk of brain swelling and microhemorrhages, particularly given the high cost of monitoring and therapy.
Commercial and Policy Implications
Payers—including commercial insurers and regional Medicare administrative contractors—frequently use Cochrane reviews to shape utilization management. This meta-analysis could lead to tighter prior authorization rules:
- Strict Inclusion/Exclusion Criteria: Insurers are likely to enforce strict eligibility limits. Payers may require confirmation of early-stage disease (MCI or mild dementia) via PET scan or CSF biomarkers, alongside genetic testing to identify APOE4 status, which carries the highest risk of ARIA.
- Mandatory Safety Monitoring: Payers are reinforcing requirements for routine MRI scans (typically at weeks 5, 9, and 14 for Leqembi) to detect asymptomatic ARIA. This safety infrastructure adds significant costs beyond the acquisition price of the drug (approximately $26,500/year for Leqembi; Kisunla’s price varies based on plaque clearance timelines).
- Pipeline Re-evaluation: The Cochrane findings emphasize the need to develop alternative mechanisms of action. This clinical feedback is prompting developers to shift capital toward anti-tau, anti-inflammatory, and neuroprotective programs to find therapies that deliver more substantial cognitive benefits.
To explore the downstream access dynamics and coverage criteria established by major commercial payers for these approved agents, see our detailed Alzheimer's anti-amyloid mAb access: Leqembi vs Kisunla.
FAQs
How many Americans are living with Alzheimer's disease, and how does that drive trial demand?
According to the Alzheimer's Association's 2025 Facts and Figures, an estimated 6.9 million Americans aged 65 and older are living with Alzheimer's dementia. This population is projected to reach 13.8 million by 2060. The massive prevalence and associated public health costs (estimated at $360 billion in 2024) drive significant government and private investment into the clinical trial pipeline.
When were Leqembi and Kisunla approved, and how do they anchor the current trial map?
The FDA granted traditional approval to Eisai/Biogen's Leqembi (lecanemab-irmb) on July 6, 2023, following an accelerated approval on January 6, 2023. Eli Lilly's Kisunla (donanemab-azbt) received FDA approval on July 2, 2024. Both drugs are approved for patients with mild cognitive impairment (MCI) or mild dementia stage of Alzheimer's disease with confirmed amyloid pathology. They serve as the active comparators or combination partners for many next-generation trials currently entering the registry.
Are GLP-1 receptor agonists being tested in Alzheimer's trials?
Yes, GLP-1 receptor agonists are being evaluated in several clinical trials. The registry contains 10 trials testing incretin therapies like semaglutide and liraglutide for Alzheimer's. These studies evaluate whether the neuroprotective and anti-inflammatory properties of GLP-1 agonists can reduce cognitive decline, capitalizing on the metabolic links between Type 2 diabetes and neurodegeneration.
What share of Alzheimer's trials are industry- versus academic-sponsored?
In our registry analysis, academic institutions, hospitals, and non-profits sponsor 60.4% (2,138 trials) of the Alzheimer's registry, while commercial industry sponsors account for 34.7% (1,228 trials). The remainder are sponsored by the NIH or other federal agencies. Academic sponsors focus heavily on early-stage mechanism exploration, biomarker discovery, and behavioral interventions, while industry sponsors fund the late-stage Phase 3 registrational trials.
Sources
- U.S. National Library of Medicine. "ClinicalTrials.gov Registry Database." Full registry extract (conditions contains 'alzheimer'). Available at: ClinicalTrials.gov
- Cummings, J., et al. "Alzheimer's disease drug development pipeline: 2026." Alzheimer's & Dementia: Translational Research & Clinical Interventions (TRCI). Published May 2026. Available at: Alzheimer's Association
- Cochrane Database of Systematic Reviews. "Lecanemab, Donanemab, and Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis." Published April 16, 2026. Available at: Cochrane Library
- Alzheimer's Association. "2025 Alzheimer's Disease Facts and Figures." Alzheimer's & Dementia. Published March 2025. Available at: PubMed Central
- U.S. Food and Drug Administration. "FDA Action on Leqembi (Lecanemab) Approval." July 6, 2023. Available at: FDA Press Announcements
- U.S. Food and Drug Administration. "FDA Action on Kisunla (Donanemab) Approval." July 2, 2024. Available at: FDA Press Announcements
